Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4914439 | 1.00 | TAAR1 (0.41) | TAAR1SLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL1004941 | 0.87 | HRH1 (0.40) | TAAR1SLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL20954473 | 0.84 | SLC6A2 (0.41) | TAAR1SLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL17956687 | 0.84 | SLC6A2 (0.41) | TAAR1SLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL3991039 | 0.84 | LMNA (0.34) | TAAR1SLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL21379413 | 0.83 | CYP3A4 (0.33) | TAAR1SLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL13915435 | 0.83 | TRPA1 (0.37) | SLC6A2SLC6A4SLC6A3CYP3A4HTT | |
| SCHEMBL21379414 | 0.83 | CYP3A4 (0.33) | TAAR1SLC6A2SLC6A4SLC6A3CYP3A4 | |
| SCHEMBL4766097 | 0.83 | TRPA1 (0.37) | SLC6A2SLC6A4SLC6A3CYP3A4HTT | |
| SCHEMBL15467266 | 0.83 | SMYD2 (0.34) | TAAR1SLC6A2SLC6A4SLC6A3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683918-A1 | NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-01-28 | — | — | EP | disclosed |
| WO-2024193541-A1 | NLRP3 INFLAMMASOME INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-09-26 | — | — | WO | disclosed |
| US-20240309048-A1 | METHOD FOR PREPARING MICROCOCCIN-BASED CARBOXYLIC ACID COMPOUND AND MICROCOCCIN-BASED CARBOXYLIC ACID COMPOUND PREPARED THEREBY | A & J SCIENCE CO., LTD. (KR) | 2024-09-19 | — | — | US | disclosed |
| US-20240277800-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MACROCOSINE COMPOUND AND METHOD FOR PREPARING MACROCOSINE COMPOUND | A & J SCIENCE CO., LTD. (KR) | 2024-08-22 | — | — | US | disclosed |
| EP-4365188-A1 | METHOD FOR PREPARING MICROCOCCIN-BASED CARBOXYLIC ACID COMPOUND AND MICROCOCCIN-BASED CARBOXYLIC ACID COMPOUND PREPARED THEREBY | A&J Science Co.,Ltd. (KR) | 2024-05-08 | — | — | EP | disclosed |
| EP-4342484-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MACROCOSINE COMPOUND AND METHOD FOR PREPARING MACROCOSINE COMPOUND | A&J Science Co.,Ltd. (KR) | 2024-03-27 | — | — | EP | disclosed |
| CN-117597352-A | Method for producing micrococcum-based carboxylic acid compound and micrococcum-based carboxylic acid compound produced thereby | A&J科学有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117597138-A | Pharmaceutical compositions comprising micrococcum compounds and methods of preparing micrococcum compounds | A&J科学有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-110105346-B | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-3995495-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2022-05-11 | — | — | EP | disclosed |
| EP-3626717-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2020-03-25 | — | — | EP | disclosed |
| US-RE47193-E1 | Selectively substituted quinoline compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| US-20180354939-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-12-13 | — | — | US | disclosed |
| US-10087174-B2 | Selectively substituted quinoline compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-10-02 | — | — | US | disclosed |
| US-20180030045-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-02-01 | — | — | US | disclosed |
| US-20160326161-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-11-10 | — | — | US | disclosed |
| US-9428495-B2 | Selectively substituted quinoline compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-08-30 | — | — | US | disclosed |
| US-20150105370-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10087174-B2 | Selectively substituted quinoline compounds | SSB, TLR7, TLR8 | TAAR1 952/4885SLC6A2 752/4885SLC6A4 1161/4885 |
| US-20240309048-A1 | METHOD FOR PREPARING MICROCOCCIN-BASED CARBOXYLIC ACID COMPOUND AND MICROCOCCIN-BASED CARBOXYLIC ACID COMPOUND PREPARED THEREBY | MCCC2, ME1, COASY | TAAR1 4656/4885SLC6A2 4786/4885SLC6A4 4541/4885 |
| US-20180030045-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | TAAR1 952/4885SLC6A2 752/4885SLC6A4 1161/4885 |
| US-20180354939-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | TAAR1 1319/4885SLC6A2 879/4885SLC6A4 1309/4885 |
| US-20160326161-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | TAAR1 952/4885SLC6A2 752/4885SLC6A4 1161/4885 |
| US-20150105370-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | TAAR1 952/4885SLC6A2 752/4885SLC6A4 1161/4885 |
| US-20240277800-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MACROCOSINE COMPOUND AND METHOD FOR PREPARING MACROCOSINE COMPOUND | SI, VIP, MLEC | TAAR1 4855/4885SLC6A2 3222/4885SLC6A4 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.